PD‑0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin‑dependent kinase‑6 and retinoblastoma protein axis

Li,Chunsheng; Qi,Ling; Bellail,Anita C.; Hao,Chunhai; Liu,Tongjun

doi:10.3892/ol.2014.1957

PD‑0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin‑dependent kinase‑6 and retinoblastoma protein axis

Authors:
- Chunsheng Li
- Ling Qi
- Anita C. Bellail
- Chunhai Hao
- Tongjun Liu
View Affiliations

Affiliations: Department of Colorectal Surgery, The Third Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Pathology, Jilin Medical College, Jilin, Jilin 132013, P.R. China, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal H3A 2B4, Canada, Department of Pathology, Montreal Neurological Institute, McGill University, Montreal H3A 2B4, Canada
Published online on: March 10, 2014 https://doi.org/10.3892/ol.2014.1957
Pages: 1673-1678

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Preclinical and clinical studies have demonstrated the anticancer activity of PD‑0332991, a selective cyclin‑dependent kinase 4/6 (CDK4/6) inhibitor, in the treatment of various types of cancer in a retinoblastoma protein (RB)‑dependent manner. However, it remains unclear whether CDK4, CDK6 or both are required for RB phosphorylation in colorectal carcinoma and thus PD‑0332991 can be used to target this CDK‑RB axis for the cancer therapy. The aim of this study was to determine whether CDK4, CDK6 and phosphorylated RB proteins were overexpressed in colorectal carcinoma tissues as compared to matched normal colorectal tissues. The results showed that knockdown of CDK6 but not CDK4 reduced RB phosphorylation and inhibited carcinoma cell growth. Thus, CDK6 plays a critical role in RB phosphorylation and cancer growth. PD‑0332991 treatment blocked RB phosphorylation and inhibited cell growth through the induction of G1 arrest of colorectal carcinoma cells. The results demonstrated that, by targeting of CDK6‑RB axis, PD‑0332991 may prove to be a novel therapeutic agent in treating colorectal carcinoma.

View Figures

View References

1	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar
2	Malumbres M: Cell cycle-based therapies move forward. Cancer Cell. 22:419–420. 2012. View Article : Google Scholar : PubMed/NCBI
3	Yu Q, Sicinska E, Geng Y, et al: Requirement for CDK4 kinase function in breast cancer. Cancer Cell. 9:23–32. 2006. View Article : Google Scholar : PubMed/NCBI
4	Puyol M, Martin A, Dubus P, et al: A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell. 18:63–73. 2010. View Article : Google Scholar
5	Hu MG, Deshpande A, Enos M, et al: A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res. 69:810–818. 2009. View Article : Google Scholar
6	Blagden S and de Bono J: Drugging cell cycle kinases in cancer therapy. Curr Drug Targets. 6:325–335. 2005. View Article : Google Scholar
7	Malumbres M, Sotillo R, Santamaria D, et al: Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell. 118:493–504. 2004. View Article : Google Scholar
8	Collins I and Garrett MD: Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol. 5:366–373. 2005. View Article : Google Scholar : PubMed/NCBI
9	Liu G, Gandara DR, Lara PN Jr, et al: A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res. 10:924–928. 2004.
10	Lapenna S and Giordano A: Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 8:547–566. 2009. View Article : Google Scholar : PubMed/NCBI
11	Fry DW, Harvey PJ, Keller PR, et al: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 3:1427–1438. 2004.
12	Toogood PL, Harvey PJ, Repine JT, et al: Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem. 48:2388–2406. 2005. View Article : Google Scholar : PubMed/NCBI
13	Wiedemeyer WR, Dunn IF, Quayle SN, et al: Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci USA. 107:11501–11506. 2010. View Article : Google Scholar
14	Finn RS, Dering J, Conklin D, et al: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11:R772009. View Article : Google Scholar
15	Michaud K, Solomon DA, Oermann E, et al: Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 70:3228–3238. 2010. View Article : Google Scholar
16	Baughn LB, Di Liberto M, Wu K, et al: A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 66:7661–7667. 2006. View Article : Google Scholar
17	Liu F and Korc M: Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 11:2138–2148. 2012. View Article : Google Scholar
18	Cen L, Carlson BL, Schroeder MA, et al: p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol. 14:870–881. 2012. View Article : Google Scholar
19	Roberts PJ, Bisi JE, Strum JC, et al: Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst. 104:476–487. 2012. View Article : Google Scholar
20	Schwartz GK, LoRusso PM, Dickson MA, et al: Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 104:1862–1868. 2011. View Article : Google Scholar
21	Flaherty KT, Lorusso PM, Demichele A, et al: Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 18:568–576. 2012. View Article : Google Scholar
22	Leonard JP, LaCasce AS, Smith MR, et al: Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 119:4597–4607. 2012. View Article : Google Scholar
23	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
24	Cole AM, Myant K, Reed KR, et al: Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss. Cancer Res. 70:8149–8158. 2010. View Article : Google Scholar
25	Garneau H, Paquin MC, Carrier JC and Rivard N: E2F4 expression is required for cell cycle progression of normal intestinal crypt cells and colorectal cancer cells. J Cell Physiol. 221:350–358. 2009. View Article : Google Scholar
26	Li B, Gao S, Wei F, Bellail AC, Hao C and Liu T: Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells. Oncol Rep. 28:15–20. 2012.
27	Wei F, Liu Y, Bellail AC, et al: K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas. Cancer Lett. 322:58–69. 2012. View Article : Google Scholar
28	Bellail AC, Olson JJ, Yang X, Chen ZJ and Hao C: A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov. 2:140–155. 2012. View Article : Google Scholar
29	Wang Q, Wei F, Li C, et al: Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma. PLoS One. 8:e731752013. View Article : Google Scholar
30	Wang Q, Wei F, Lv G, et al: The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin. BMC Cancer. 13:5212013. View Article : Google Scholar
31	Rubin SM: Deciphering the retinoblastoma protein phosphorylation code. Trends Biochem Sci. 38:12–19. 2013. View Article : Google Scholar
32	Meyerhardt JA and Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005. View Article : Google Scholar : PubMed/NCBI